Kiromic BioPharma is an artificial intelligence driven, end-to-end Chimeric Antigen Receptor T cell and gene therapy company. Co.'s Procel, Isocel, and Deltacel platforms consist of allogeneic cell therapy product candidates that are in the preclinical development stage. Co.'s Procel product candidate consists of engineered GDTs that target PD-L1. Co.'s Isocel product candidate consists of engineered Gamma Delta T cells that target Mesothelin Isoform 2 positive tumors. Co.'s Deltacel product candidate consists of non-engineered GDTs that have been expanded and activated ex- vivo through a process, and are used to treat solid tumors regardless of the specific tumor antigen expression. The KRBP stock yearly return is shown above.
The yearly return on the KRBP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KRBP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|